SCHEMBL6965004

SCHEMBL6965004

COc1ccc(CCOS(=O)(=O)c2ccc(C)cc2)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP8 P22894 1/20 0.47
MMP13 P45452 1/20 0.47
ALDH1A1 P00352 5/20 0.43
POLB P06746 2/20 0.43
MAPT P10636 1/20 0.42
TSHR P16473 4/20 0.42
GAA P10253 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103834 0.82 STAT3 (0.48) MMP1MMP2MMP9MMP8MMP13
SCHEMBL30844048 0.81 MAPT (0.44) MMP1MMP2MMP9MMP8MMP13
SCHEMBL20535502 0.79 PKM (0.47)
SCHEMBL6954162 0.78 STAT3 (0.39) ALDH1A1POLBTSHRKMT2ASMN1; SMN2
SCHEMBL6994087 0.78 LMNA (0.53) ALDH1A1POLBMAPTTSHRKMT2A
SCHEMBL26655207 0.77 ALDH1A1 (0.47) ALDH1A1POLBMAPTGAAKMT2A
SCHEMBL2352786 0.76 PTGS1 (0.49) ALDH1A1POLBMAPTGAAKMT2A
SCHEMBL2881816 0.76 LMNA (0.43) ALDH1A1POLBMAPTKMT2ASMN1; SMN2
SCHEMBL26655501 0.75 MAPT (0.45) ALDH1A1POLBMAPTGAAKMT2A
SCHEMBL31363722 0.74 MMP1 (0.52) MMP1MMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562808-B1 Calcium channel antagonists effective in treating intestinal diseases caused by abnormal acceleration of the contraction of intestinal tracts such as irritable bowel syndrome, without significant cardiac effects AJINOMOTO CO., INC. (JP) 2003-05-13 US disclosed
EP-1020466-B1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME AJINOMOTO KK (JP) 2003-02-19 EP disclosed
EP-1020466-A1 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2000-07-19 EP disclosed